A list of more than 80 compounds in clinical trials for Alzheimer’s disease, released by PhRMA, inevitably brings to mind all those that failed previously. But researchers view the new list as a source of hope, increasingly confident a breakthrough may be among them. Alzheimer’s News Today spoke to two Alzheimer's experts about expectations for these current studies. In those interviews, it became clear that — in contrast to what most people assume — collaboration plays an important role in pharmaceutical company work in this field. Academic institutions are also involved in these collaborative efforts. And, in their midst, the Alzheimer’s Association is a driving force, funding collaboration initiatives and offering scientists a platform to come together to discuss research difficulties and progress. What are these initiatives? And how do they help advance potential treatments for Alzheimer’s disease?